Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 70,453 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the transaction, the insider directly owned 793 shares in the company, valued at approximately $22,283.30. The trade was a 98.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Septerna Price Performance

Shares of NASDAQ:SEPN traded up $0.70 during midday trading on Wednesday, reaching $28.83. 200,300 shares of the company’s stock were exchanged, compared to its average volume of 306,764. Septerna, Inc. has a fifty-two week low of $4.66 and a fifty-two week high of $32.63. The firm’s 50 day simple moving average is $26.93 and its two-hundred day simple moving average is $22.65. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -19.09 and a beta of 3.46.

Wall Street Analyst Weigh In

Several research firms recently commented on SEPN. JonesTrading began coverage on Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price on the stock. Truist Financial started coverage on Septerna in a report on Monday, December 15th. They issued a “buy” rating and a $34.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, HC Wainwright upped their target price on shares of Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Septerna presently has an average rating of “Moderate Buy” and an average target price of $38.00.

Institutional Investors Weigh In On Septerna

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its stake in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after acquiring an additional 1,260,409 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Septerna by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after purchasing an additional 104,394 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Septerna by 8.1% in the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after acquiring an additional 100,000 shares during the period. ADAR1 Capital Management LLC grew its position in Septerna by 38.9% during the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock worth $22,130,000 after buying an additional 329,264 shares in the last quarter. Finally, First Light Asset Management LLC acquired a new stake in Septerna during the fourth quarter worth $17,308,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.